MedTrace Logo

Test-retest Study With [18F]PI-2620 in PSP-RS and NDC

NCT05187546 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-05-18

No results posted yet for this study

Summary

The overall goal of this protocol is to evaluate the imaging characteristics of \[18F\]PI-2620 using positron emission tomography (PET) in patients with progressive supranuclear palsy, Richardson's syndrome (PSP-RS)

Conditions

Interventions

DRUG

[18F]-PI2620

\[18F\]PI-2620 is a radioactive diagnostic agent being developed for the indication of PET imaging of the brain to detect tau pathology in adult patients who are being evaluated for neurodegenerative decline. All patients will receive two administrations of \[18F\]PI-2620 at a radioactive dose of 185 megabecquerel (MBq).

Sponsors & Collaborators

  • Life Molecular Imaging GmbH

    lead INDUSTRY

Principal Investigators

  • Andrew Stephens, MD, PhD · Life Molecular Imaging

  • Matthias Brendel, MD · Department of Nuclear Medicine, University of Munich

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2024-02-29
Completion
2024-03-05

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05187546 on ClinicalTrials.gov